News
SRZN
31.61
-0.19%
-0.06
Surrozen prices 1.89M shares of common stock at $31.67
TipRanks · 2d ago
Surrozen Is Maintained at Buy by Guggenheim
Dow Jones · 3d ago
Guggenheim Maintains Buy on Surrozen, Raises Price Target to $80
Benzinga · 3d ago
Surrozen (SRZN) Receives a Buy from Guggenheim
TipRanks · 3d ago
Surrozen price target raised to $80 from $42 at Guggenheim
TipRanks · 3d ago
Surrozen reports Q3 EPS ($11.02) vs. ($8.36) last eyar
TipRanks · 5d ago
Surrozen Price Target Raised to $62.00/Share From $40.00 by Cantor Fitzgerald
Dow Jones · 5d ago
Surrozen Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 5d ago
Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62
Benzinga · 5d ago
H.C. Wainwright Keeps Their Buy Rating on Surrozen (SRZN)
TipRanks · 5d ago
Surrozen GAAP EPS of -$11.02 misses by $9.92
Seeking Alpha · 5d ago
Surrozen: The Wnt Science Is Compelling, But The Stock Prices In Too Much Success
Seeking Alpha · 6d ago
Weekly Report: what happened at SRZN last week (1102-1106)?
Weekly Report · 11/09 09:31
Consonance-Hfw Acq Corp: Did Boehringer's Data Just Validate the Entire Wnt Platform?
Barchart · 11/05 16:06
Weekly Report: what happened at SRZN last week (1026-1030)?
Weekly Report · 11/02 09:31
Weekly Report: what happened at SRZN last week (1019-1023)?
Weekly Report · 10/26 09:31
Surrozen Raises $95 Million, Extends Cash Runway
TipRanks · 10/20 21:29
Weekly Report: what happened at SRZN last week (1012-1016)?
Weekly Report · 10/19 09:31
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Gilead Sciences (GILD) and Biohaven Ltd. (BHVN)
TipRanks · 10/12 17:00
Weekly Report: what happened at SRZN last week (1005-1009)?
Weekly Report · 10/12 09:33
More
Webull provides a variety of real-time SRZN stock news. You can receive the latest news about Surrozen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.